JP5873807B2 - Ｂ細胞を形質導入するためのベクターおよび方法 - Google Patents

Ｂ細胞を形質導入するためのベクターおよび方法 Download PDF

Info

Publication number
JP5873807B2
JP5873807B2 JP2012548181A JP2012548181A JP5873807B2 JP 5873807 B2 JP5873807 B2 JP 5873807B2 JP 2012548181 A JP2012548181 A JP 2012548181A JP 2012548181 A JP2012548181 A JP 2012548181A JP 5873807 B2 JP5873807 B2 JP 5873807B2
Authority
JP
Japan
Prior art keywords
cells
cell
transduced
nucleic acid
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012548181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516194A5 (enExample
JP2013516194A (ja
Inventor
ショルツ，マシュー，レイン
ハービッグ，エリック，ジェイ．
Original Assignee
イミュソフト コーポレーション
イミュソフト コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュソフト コーポレーション, イミュソフト コーポレーション filed Critical イミュソフト コーポレーション
Publication of JP2013516194A publication Critical patent/JP2013516194A/ja
Publication of JP2013516194A5 publication Critical patent/JP2013516194A5/ja
Application granted granted Critical
Publication of JP5873807B2 publication Critical patent/JP5873807B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012548181A 2010-01-08 2011-01-07 Ｂ細胞を形質導入するためのベクターおよび方法 Active JP5873807B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29352210P 2010-01-08 2010-01-08
US61/293,522 2010-01-08
PCT/US2011/020578 WO2011085247A2 (en) 2010-01-08 2011-01-07 Vectors and methods for transducing b cells

Publications (3)

Publication Number Publication Date
JP2013516194A JP2013516194A (ja) 2013-05-13
JP2013516194A5 JP2013516194A5 (enExample) 2014-02-27
JP5873807B2 true JP5873807B2 (ja) 2016-03-01

Family

ID=44306176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012548181A Active JP5873807B2 (ja) 2010-01-08 2011-01-07 Ｂ細胞を形質導入するためのベクターおよび方法

Country Status (7)

Country Link
US (1) US9074223B2 (enExample)
EP (1) EP2521789B1 (enExample)
JP (1) JP5873807B2 (enExample)
CA (1) CA2786664C (enExample)
DK (1) DK2521789T3 (enExample)
ES (1) ES2617749T3 (enExample)
WO (1) WO2011085247A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010823B1 (pt) * 2011-11-07 2021-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial
US10240125B2 (en) * 2013-03-14 2019-03-26 Immusoft Corporation Methods for in vitro memory B cell differentiation and transduction with VSV-G pseudotyped viral vectors
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
CA2914595C (en) * 2014-05-19 2022-12-13 F. Hoffmann-La Roche Ag Method for producing antibodies using ovine b-cells and uses thereof
DK3234107T3 (da) 2014-12-19 2022-10-17 Immusoft Corp B-celler til in vivo-levering af terapeutiske midler
WO2016161446A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
CN109072192B (zh) * 2016-02-16 2024-02-09 杜克大学 用于扩展和分化生产抗体的b细胞的方法
WO2018201071A1 (en) * 2017-04-27 2018-11-01 Immusoft Corporation B cells for in vivo delivery of therapeutic agents and dosages thereof
MX2020004063A (es) 2017-10-20 2020-10-05 Hutchinson Fred Cancer Res Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados.
AU2019233929B2 (en) 2018-03-16 2025-05-29 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
RU2714380C1 (ru) * 2018-12-28 2020-02-14 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения цитотоксических т-лимфоцитов, экспрессирующих химерные рецепторы
WO2022040202A1 (en) * 2020-08-17 2022-02-24 Northwestern University B-cell based immunotherapy for the treatment of glioblastoma and other cancers
WO2025106856A1 (en) 2023-11-15 2025-05-22 Immusoft Corporation Migratory modified differentiated b cells for cancer therapy
WO2025147573A2 (en) 2024-01-05 2025-07-10 Immusoft Corporation Glp-1 expressing modified b cells for the treatment of metabolic disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
ES2430991T3 (es) * 2000-06-01 2013-11-22 Dnavec Research Inc. Vector retroviral seudotipo que contiene proteína de membrana que tiene actividad hemaglutinina
WO2003068819A1 (en) * 2001-12-22 2003-08-21 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
EP1975239A1 (en) 2006-09-27 2008-10-01 Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening
EP2358868B1 (en) 2008-11-21 2014-11-12 California Institute of Technology In vitro human b lymphopoiesis culture system

Also Published As

Publication number Publication date
EP2521789B1 (en) 2016-12-14
CA2786664C (en) 2020-03-10
EP2521789A4 (en) 2013-08-21
WO2011085247A3 (en) 2011-11-10
WO2011085247A4 (en) 2011-12-29
DK2521789T3 (en) 2017-03-27
JP2013516194A (ja) 2013-05-13
US9074223B2 (en) 2015-07-07
CA2786664A1 (en) 2011-07-14
ES2617749T3 (es) 2017-06-19
WO2011085247A2 (en) 2011-07-14
US20130143267A1 (en) 2013-06-06
EP2521789A2 (en) 2012-11-14

Similar Documents

Publication Publication Date Title
US20230081163A1 (en) B cells for in vivo delivery of therapeutic agents
JP5873807B2 (ja) Ｂ細胞を形質導入するためのベクターおよび方法
US20250243459A1 (en) Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
WO2018201071A1 (en) B cells for in vivo delivery of therapeutic agents and dosages thereof
CA2971430C (en) B cells for in vivo delivery of therapeutic agents
HK1178934A (en) Vectors and methods for transducing b cells
HK1178934B (en) Vectors and methods for transducing b cells
HK1245834B (en) B cells for in vivo delivery of therapeutic agents
HK1220230B (en) Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160118

R150 Certificate of patent or registration of utility model

Ref document number: 5873807

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250